These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 10710827)
1. Review--antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach. Gionchetti P; Rizzello F; Venturi A; Ugolini F; Rossi M; Brigidi P; Johansson R; Ferrieri A; Poggioli G; Campieri M Eur Rev Med Pharmacol Sci; 1999; 3(1):27-30. PubMed ID: 10710827 [TBL] [Abstract][Full Text] [Related]
2. Rifaximin in the treatment of inflammatory bowel disease. Guslandi M World J Gastroenterol; 2011 Nov; 17(42):4643-6. PubMed ID: 22180705 [TBL] [Abstract][Full Text] [Related]
3. Management of inflammatory bowel disease: does rifaximin offer any promise? Gionchetti P; Rizzello F; Morselli C; Romagnoli R; Campieri M Chemotherapy; 2005; 51 Suppl 1():96-102. PubMed ID: 15855753 [TBL] [Abstract][Full Text] [Related]
4. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases. Sartor RB Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():27-36. PubMed ID: 26618923 [TBL] [Abstract][Full Text] [Related]
5. Role of antibiotics for treatment of inflammatory bowel disease. Nitzan O; Elias M; Peretz A; Saliba W World J Gastroenterol; 2016 Jan; 22(3):1078-87. PubMed ID: 26811648 [TBL] [Abstract][Full Text] [Related]
6. Role of Rifaximin in Inflammatory Bowel Disease Treatment. Scribano ML Mini Rev Med Chem; 2015; 16(3):225-9. PubMed ID: 26202194 [TBL] [Abstract][Full Text] [Related]
7. Gut microbiota and inflammatory bowel disease: the role of antibiotics in disease management. Kerman DH; Deshpande AR Postgrad Med; 2014 Jul; 126(4):7-19. PubMed ID: 25141239 [TBL] [Abstract][Full Text] [Related]
8. [Clinical and pharmacological aspects of rifaximin, local antibiotic therapy in intestinal disorders]. Gasztonyi B; Hunyady B Orv Hetil; 2004 Oct; 145(43):2177-81. PubMed ID: 15575494 [TBL] [Abstract][Full Text] [Related]
9. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279 [TBL] [Abstract][Full Text] [Related]
10. Antimicrobials in the management of inflammatory bowel disease. Gionchetti P; Rizzello F; Lammers KM; Morselli C; Tambasco R; Campieri M Digestion; 2006; 73 Suppl 1():77-85. PubMed ID: 16498255 [TBL] [Abstract][Full Text] [Related]
11. Rifaximin: a nonabsorbed oral antibiotic. Baker DE Rev Gastroenterol Disord; 2005; 5(1):19-30. PubMed ID: 15741929 [TBL] [Abstract][Full Text] [Related]
13. Antibiotics and probiotics in inflammatory bowel disease: why, when, and how. Prantera C; Scribano ML Curr Opin Gastroenterol; 2009 Jul; 25(4):329-33. PubMed ID: 19444096 [TBL] [Abstract][Full Text] [Related]
14. Antibiotics for inflammatory bowel disease: do they work? Guslandi M Eur J Gastroenterol Hepatol; 2005 Feb; 17(2):145-7. PubMed ID: 15674090 [TBL] [Abstract][Full Text] [Related]
15. Antibiotics and probiotics in treatment of inflammatory bowel disease. Gionchetti P; Rizzello F; Lammers KM; Morselli C; Sollazzi L; Davies S; Tambasco R; Calabrese C; Campieri M World J Gastroenterol; 2006 Jun; 12(21):3306-13. PubMed ID: 16733845 [TBL] [Abstract][Full Text] [Related]
16. Role of antibiotics in the management of inflammatory bowel disease: a review. Rubin DT; Kornblunth A Rev Gastroenterol Disord; 2005; 5 Suppl 3():S10-5. PubMed ID: 17713454 [TBL] [Abstract][Full Text] [Related]
17. Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases. Schultz M; Schölmerich J; Rath HC Dig Dis; 2003; 21(2):105-28. PubMed ID: 14571109 [TBL] [Abstract][Full Text] [Related]
18. Practical Considerations and the Intestinal Microbiome in Disease: Antibiotics for IBD Therapy. Fedorak RN; Ismond KP Dig Dis; 2016; 34(1-2):112-21. PubMed ID: 26982586 [TBL] [Abstract][Full Text] [Related]
19. New trends in non-absorbable antibiotics in gastrointestinal disease. Di Febo G; Calabrese C; Matassoni F Ital J Gastroenterol; 1992; 24(9 Suppl 2):10-3. PubMed ID: 1486193 [TBL] [Abstract][Full Text] [Related]
20. Use of rifaximin in gastrointestinal and liver diseases. Shayto RH; Abou Mrad R; Sharara AI World J Gastroenterol; 2016 Aug; 22(29):6638-51. PubMed ID: 27547007 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]